Search Result

Results for "

PG-PS

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) AMPK (1) Amylases (1) Amyloid-β (1) Antibiotic (4) Apoptosis (11) Autophagy (3) Bacterial (4) Bcl-2 Family (1) BCRP (10) Beta-secretase (2) c-Met/HGFR (2) Calcium Channel (9) Cannabinoid Receptor (1) Carbonic Anhydrase (1) Caspase (1) CCR (1) CDK (1) Cytochrome P450 (16) Dopamine β-hydroxylase (1) Drug Metabolite (3) Endogenous Metabolite (10) Ferroptosis (1) Glucosidase (1) HCV Protease (1) Hedgehog (2) HIV (7) HIV Protease (7) iGluR (2) Interleukin Related (1) Isotope-Labeled Compounds (6) Liposome (1) Microtubule/Tubulin (2) Mitochondrial Metabolism (1) NF-κB (4) Opioid Receptor (1) P-glycoprotein (95) p38 MAPK (1) Parasite (2) PARP (1) Potassium Channel (1) PPAR (2) Reactive Oxygen Species (1) SARS-CoV (7) Small Interfering RNA (siRNA) (1) TAM Receptor (2) TNF Receptor (1) Wee1 (2) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (97) Cardiovascular Disease (10) Infection (14) Inflammation/Immunology (9) Metabolic Disease (9) Neurological Disease (8)
Oligonucleotides:	Pre-designed siRNA Sets (1) Phospholipids (1) siRNAs (1)

128

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-119823

PGP-4008	P-glycoprotein	Cancer
PGP-4008 is a specific P-glycoprotein (Pgp) inhibitor. PGP-4008 inhibits tumor growth in a murine syngeneic Pgp-mediated multiple agent resistance (MDR) solid tumor model when given in combination with Doxorubicin .

HY-159614

*PG-PS*	TNF Receptor Interleukin Related	Inflammation/Immunology
PG-PS is a complex composed of streptococcal cell wall peptidoglycans and polysaccharides with pro-inflammatory and arthritis-inducing activity. PG-PS can be used to establish arthritis models. PG-PS can cause inflammation and joint damage, increase the expression of pro-inflammatory cytokines (TNF-α and IL-1β), and disrupt cellular redox balance .

HY-144366

P-gp inhibitor 3	P-glycoprotein	Cancer
P-gp inhibitor 3 is an effective P-glycoprotein (P-gp) inhibitor. P-gp inhibitor 3 inhibits the efflux function of P-gp by activating P-gp ATPase. P-gp inhibitor 3 has relatively stronger multidrug resistance (MDR) reversal ability and enhances the anti-tumor activity of Paclitaxel .

HY-155032

P-gp inhibitor 15	P-glycoprotein	Cancer
P-gp inhibitor 15 (compound 7a) is a nonsubstrate inhibitor of P-glycoprotein (Pgp). P-gp inhibitor 15 inhibits Pgp-ATPase activity，and interfers Pgp-mediated Rhodamine123 efflux. P-gp inhibitor 15 also enhances the inhibitory efficacy of Paclitaxel (HY-B0015)，inhibits tumor progress in nude mice KBV xenograft tumors model .

HY-157483

P-gp inhibitor 18	P-glycoprotein	Cancer
P-gp inhibitor 18 (compound 6G) is a potent inhibitor of *P-gp. P-gp* inhibitor 18 inhibits rhodamine 123 efflux in the P-gp overexpressed leukemia cells, K562/Dox .

HY-162040

P-gp inhibitor 17	P-glycoprotein	Cancer
P-gp inhibitor 17 (compound 2g) is a *P-gp* inhibitor directly interacted with the transmembrane domain of *P-gp. P-gp* inhibitor 17 can be used for P-gp-mediated multidrug-resistant in tumor cells study .

HY-112912

P-gp modulator 1	P-glycoprotein	Cancer
P-gp modulator 1 is a high affinity, orally available modulator of P-glycoprotein (Pgp), can reverse the Pgp-mediated multidrug resistance ((MDR) .

HY-161260

P-gp inhibitor 20	P-glycoprotein	Cancer
P-gp inhibitor 20 (compound H27) is a low cytotoxicity P-glycoprotein (P-gp) inhibitor. P-gp inhibitor 20 inhibits the efflux function of P-gp in a dose-dependent manner (without affecting the expression of P-gp), thereby reversing the multidrug resistance (MDR) of MCF-7/ADR cells, with an IC₅₀ value of 46.6 nM. P-gp inhibitor 20 can be used for cancer research .

HY-N144114

P-gp inhibitor 2	P-glycoprotein	Cancer
P-gp inhibitor 2 is a potent *P-gp* inhibitor. P-gp inhibitor 2 shows reverse Doxorubicin resistance (IC₅₀=0.22 µM) in P-gp overexpressing human colorectal carcinoma cells (SW600 Ad300) .

HY-149981

P-gp inhibitor 13	P-glycoprotein	Cancer
P-gp inhibitor 13 is a *P-gp* inhibitor. P-gp inhibitor 13 can reverse P-glycoprotein-mediated paclitaxel resistance in A2780/T cell. P-gp inhibitor 13 can be used for the research of advanced acute myeloid leukemia .

HY-149813

P-gp inhibitor 14	P-glycoprotein	Cancer
P-gp inhibitor 14 (Compound 8a) is a high affinity *P-gp* inhibitor. P-gp inhibitor 14 reverses P-gp-mediated multidrug resistance (EC₅₀=48.74 nM). P-gp inhibitor 14 has a weak inhibitory effect on CYP3A4 activity .

HY-159085

P-gp inhibitor 24	P-glycoprotein	Cancer
P-gp inhibitor 24 (Compound 10) is an inhibitor for P-glycoprotein (P-gp)), that inhibits the P-gp mediated fluorescent dye efflux. P-gp inhibitor 24 exhibits multidrug resistance (MDR) reversal effect, enhances the cytotoxicity of Vincristine (HY-N0488) and Etoposide (HY-13629) in cancer cells .

HY-146117

P-gp modulator 2	P-glycoprotein	Cancer
P-gp modulator 2 (Compound 27) is a potent, competitive, allosteric P-glycoprotein (P-gp) modulator .

HY-146118

P-gp modulator 3	P-glycoprotein	Cancer
P-gp modulator 3 (Compound 37) is a potent, competitive, allosteric P-glycoprotein (P-gp) modulator .

HY-162447

P-gp inhibitor 22	P-glycoprotein Apoptosis	Cancer
P-gp inhibitor 22 is a P-glycoprotein (P-gp) inhibitor that effectively inhibits P-pg and efflux function. P-gp inhibitor 22 induces apoptosis and accumulation of MCF-7/ADR cells processed in the S phase .

HY-158435

P-gp inhibitor 23	P-glycoprotein Cytochrome P450	Cancer
P-gp inhibitor 23 (compound 14F) is a potent inhibitor of *P-gp* and CYP3A4, with the EC₅₀ and IC₅₀ of 28 nM and 223 nM, respectively .

HY-150565

P-gp inhibitor 5	P-glycoprotein	Cancer
P-gp inhibitor 5 is a potent P-glycoprotein (P-gp) inhibitor. P-gp inhibitor 5 has antiproliferative activity against certain cancer cell lines. P-gp inhibitor 5 is effective in reversing the multidrug resistance (MDR) phenotype in ABCB1/Flp-In ^TM-293 and KBvin cells by restoring their sensitivity to Vincristine (HY-N0488A) and Paclitaxel (HY-B0015) .

HY-162822

P-gp modulator-5	P-glycoprotein	Cancer
P-gp modulator-5 (compound 25) is a modulator of *P-gp* and can inhibit the proliferation of multidrug resistant (MDR) tumors. P-gp modulator-5 inhibits the activity of drug efflux pumps in MDR cells, leading to a large accumulation of ROS and altered cell cycle profiles .

HY-157330

P-gp inhibitor 16	P-glycoprotein Apoptosis	Cancer
P-gp inhibitor 16 (compound 14) is a p-glycoprotein inhibitor. P-gp inhibitor 16 significantly increases Doxorubicin-induced apoptosis and shows anticancer effects .

HY-RS10394

PGP Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
PGP Human Pre-designed siRNA Set A contains three designed siRNAs for PGP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PGP Human Pre-designed siRNA Set A PGP Human Pre-designed siRNA Set A

HY-161645

P-gp modulator-4	P-glycoprotein	Cancer
P-gp modulator-4 (compound 4c) inhibits the efflux function of P-glycoprotein (P-gp). P-gp modulator-4 shows multidrug resistance (MDR) in cancer reversal activity (IC₅₀ of Paclitaxel (HY-B0015) = 8.80, reversal fold = 211.8) .

HY-157484

P-gp inhibitor 19	P-glycoprotein	Cancer
P-gp inhibitor 19 (Compound 6i) is a P-gp inhibitor. P-gp inhibitor 19 can inhibit the efflux of rhodamine 123 (HY-D0816) in P-gp-overexpressing leukemia cells K562/Dox and also restore the sensitivity of DOX-resistant cells .

HY-U00247

MCI826	P-glycoprotein	Cancer
MCI826 is a P-glycoprotein (P-gp) antagonist.

HY-162396

P-gp inhibitor 21	P-glycoprotein	Cancer
P-gp inhibitor 21 (Compound 56) is an inhibitor for P-glycoprotein (P-gp) transport, which reverses P-gp-mediated multidrug resistance (MDR) and exhibits antitumor efficacy in mice without significant cytotoxicity .

HY-N10562

Mutabilol	P-glycoprotein	Cancer
Mutabilol (compound 1) is a potent p-glycoprotein (P-gp) regulator. Mutabilol is a nature product could be isolated from Plectranthus mutabilis leaves. Mutabilol increases the P-gp expression in NCI-H460/R cells .

HY-19626

NSC23925	P-glycoprotein	Cancer
NSC23925 is a novel, selective and effective P-glycoprotein (Pgp) inhibitor.

HY-146391

P-gp inhibitor 4	P-glycoprotein	Cancer
P-gp inhibitor 4 (Compound 8b) is a selective P-glycoprotein modulator with an EC₅₀ of 94 nM. P-gp inhibitor 4 increases agent transport across gastro-intestinal barrier and recovers doxorubicin toxicity in multidrug resistant cancer cells .

HY-126940

Furanodiene	Reactive Oxygen Species P-glycoprotein Apoptosis	Cancer
Furanodiene is a natural terpenoid isolated from Rhizoma Curcumae. Furanodiene plays anti-cancer effects through anti-angiogenesis and inducing ROS production, DNA strand breaks and apoptosis. Furanodiene suppresseed efflux transporter *Pgp* (P-glycoprotein) function and reduced Pgp protein level .

HY-162369

PID-9	P-glycoprotein	Cancer
PID-9 is a P-glycoprotein inhibitor. PID-9 has multidrug resistance (MDR) reversal activity (IC₅₀ = 0.1338 μM) and low toxicity. PID-9 inhibits the transport function of P-gp without downregulating P-gp expression .

HY-101791

P-gp inhibitor 1	P-glycoprotein	Cancer
P-gp inhibitor 1 is a novel inhibitor reversing P-glycoprotein-mediated multidrug resistance.

HY-W700684

N-Didesmethyl Loperamide R 21345	Others	Others
N-Didesmethyl Loperamide is a metabolite of Loperamide; a new and improved PET radiotracer for imaging P-gp function.

HY-B0777

Moxidectin 1 Publications Verification CL301423	Antibiotic BCRP P-glycoprotein Parasite	Infection
Moxidectin (CL301423) is an orally active macrolide (ML) anthelmintic for the prevention and control of heartworms and roundworms. Moxidectin is also a substrate of BCRP and P-glycoprotein (P-gp) in vivo, and is secreted into breast milk and effluxed from the host and parasite mediated by Bcrp1 and P-gp. This may be related to the presence of chemical residues in milk .

HY-149360

P-gb-IN-1	P-glycoprotein	Cancer
P-gb-IN-1 (compound Ⅲ-8), a 2,5-disubstituted furan derivative, is a highly effective, broadspectrum P-glycoprotein (P-gp) inhibitor. P-gb-IN-1 displayed the reversal activity by inhibiting P-gp efflux. P-gb-IN-1 has a potent affinity to P-gp by forming H-bond interactions with residues Asn 721 and Met 986. P-gb-IN-1 possesses broad-spectrum reversal activity and low toxicity in MCF-7/ADR cells .

HY-10550A

Tariquidar methanesulfonate, hydrate 45+ Cited Publications XR9576 methanesulfonate, hydrate	P-glycoprotein	Cancer
Tariquidar methanesulfonate, hydrate (XR9576 methanesulfonate, hydrate) is a potent and specific inhibitor of P-glycoprotein (P-gp) with a K_d of 5.1 nM.

HY-N1457

Chrysosplenetin	P-glycoprotein Cytochrome P450 Ferroptosis	Metabolic Disease
Chrysosplenetin is one of the polymethoxylated flavonoids in Artemisia annua L. (Compositae) and other several Chinese herbs. Chrysosplenetin inhibits *P-gp* activity and reverses the up-regulated P-gp and MDR1 levels induced by artemisinin (ART). Chrysosplenetin significantly augments the rat plasma level and anti-malarial efficacy of ART, partially due to the uncompetitive inhibition effect of Chrysosplenetin on rat CYP3A .

HY-144393

P-gp/BCRP-IN-1	BCRP	Cancer
P-gp/BCRP-IN-1 (compound 19) is a potential, relatively safe, orally active and efficient efflux transporter (P-gp and BCRP) inhibitor. P-gp/BCRP-IN-1 exerts resistance reversal by inhibiting the efflux function of *P-gp* and BCRP. P-gp/BCRP-IN-1 can overcome the resistance and improve the oral bioavailability of PTX (Paclitaxel) .

HY-149277

FM04	P-glycoprotein	Cancer
FM04 is a potent P-glycoprotein (P-gp) inhibitor (EC₅₀=83 nM). FM04 inhibits P-gp in 2 mechanism: (1)FM04 binds to Q1193, followed by interacting with the functionally critical residues H1195 and T1226; or (2)FM04 binds to I1115 (a functionally critical residue itself), disrupting the R262-Q1081-Q1118 interaction pocket and uncoupling ICL2-NBD2 interaction and thereby inhibiting P-gp .

HY-10550

Tariquidar 45+ Cited Publications XR9576	P-glycoprotein	Cancer
Tariquidar (XR9576) is a potent and specific inhibitor of P-glycoprotein (P-gp) with the high affinity (K_d=5.1 nM) .

HY-110377

Tariquidar dihydrochloride XR9576 dihydrochloride	P-glycoprotein	Cancer
Tariquidar dihydrochloride (XR9576 dihydrochloride) is a potent and specific inhibitor of P-glycoprotein (P-gp) with the high affinity (K_d=5.1 nM) .

HY-W001601

Budipine	iGluR	Neurological Disease
Budipine is an anti-parkinson agent. Budipine also is a substrate of P-glycoprotein (P-gp), is mediated the uptake into the brain by P-gp. Budipine also is N-methyl-d-aspartate (NMDA) antagonist, and has indirect dopaminergic effects through an improved dopamine release, the inhibition of monoamine oxidase type B (MAO-B). Budipine can be used for the research of CNS disorders include Parkinson disease .

HY-N7120

Penicillin G procaine hydrate PGP hydrate	Bacterial Antibiotic	Infection
Penicillin G Procaine hydrate (PGP hydrate), a β-lactam antibiotic, is a crystalline complex produced by chemically combining penicillin G with procaine .

HY-W009141

1-Monopalmitin Glyceryl palmitate	P-glycoprotein	Cancer
1-Monopalmitin, a bitter melon extract, inhibits the P-glycoprotein (P-gp) activity in intestinal Caco-2 cells .

HY-B0777R

Moxidectin (Standard) CL301423 (Standard)	Antibiotic BCRP P-glycoprotein Parasite	Infection
Moxidectin (Standard) is the analytical standard of Moxidectin. This product is intended for research and analytical applications. Moxidectin (CL301423) is an orally active macrolide (ML) anthelmintic for the prevention and control of heartworms and roundworms. Moxidectin is also a substrate of BCRP and P-glycoprotein (P-gp) in vivo, and is secreted into breast milk and effluxed from the host and parasite mediated by Bcrp1 and P-gp. This may be related to the presence of chemical residues in milk .

HY-100750

Norverapamil hydrochloride 1 Publications Verification (±)-Norverapamil hydrochloride; D591 hydrochloride	Calcium Channel P-glycoprotein Drug Metabolite	Cardiovascular Disease
Norverapamil hydrochloride ((±)-Norverapamil hydrochloride), an N-demethylated metabolite of Verapamil, is a L-type calcium channel blocker and a P-glycoprotein (P-gp) function inhibitor .

HY-135328

Norverapamil (±)-Norverapamil; D591	Calcium Channel P-glycoprotein Drug Metabolite	Cardiovascular Disease
Norverapamil ((±)-Norverapamil), an N-demethylated metabolite of Verapamil, is a L-type calcium channel blocker and a P-glycoprotein (P-gp) function inhibitor .

HY-163204

RhQ-DMB	P-glycoprotein	Cancer
RhQ-DMB is a potent inhibitor of *P-gp*. RhQ-DMB exhibits high affinity and inhibitory activity in yeast strains expressing CmABCB1 .

HY-158236

ORL1 antagonist 2	Opioid Receptor	Neurological Disease
ORL1 antagonist 2 (1B) is an opioid receptor-Like 1 (ORL1) antagonist, usd in P-glycoprotein (P-gp) research .

HY-107643

Reversan CBLC4H10	P-glycoprotein	Cancer
Reversan (CBLC4H10) is a potent and nontoxic multidrug resistance-associated protein 1 (MRP1) and P-glycoprotein (Pgp) inhibitor .

HY-N0689

Evodine	P-glycoprotein	Cancer
Evodine, the major limonoid of Evodiae Fuctus, is a potent *P-gp* inhibitor. Evodine has protection against glutamateinduced toxicity by preserving the antioxidant defense system .

HY-W140488

1,2-Didecanoyl-sn-glycero-3-phosphoethanolamine 10:0 PE	Liposome	Cancer
1,2-Didecanoyl-sn-glycero-3-phosphoethanolamine, a phospholipid, showes very promising P-gp inhibitory results at a concentration of 0.3 mM.

Cat. No.	Product Name

HY-L011

Membrane Transporter/Ion Channel Compound Library

1,497 compounds

Most of molecules enter or leave cells mainly via membrane transport proteins, which play important roles in several cellular functions, including cell metabolism, ion homeostasis, signal transduction, the recognition process in the immune system, energy transduction, etc. There are three major types of transport proteins, ATP-powered pumps, channel proteins and transporters. Transport proteins such as channels and transporters play important roles in the maintenance of intracellular homeostasis, and mutations in these transport protein genes have been identified in the pathogenesis of a number of hereditary diseases. In the central nervous system, ion channels have been linked to, but not limited to, many diseases such asataxias, paralyses, epilepsies, and deafness. This indicates the roles of ion channels in the initiation and coordination of movement, sensory perception, and encoding and processing of information. Ion channels are a major class of drug targets in drug development.

MCE designs a unique collection of 1,497 smal-molecule modulators that can be used for the research of Ion Channel and Membrane Transporter or high throughput screening (HTS) related drug discovery.

Cat. No.	Product Name	Target	Research Area

HY-162396

P-gp inhibitor 21	P-glycoprotein	Cancer
P-gp inhibitor 21 (Compound 56) is an inhibitor for P-glycoprotein (P-gp) transport, which reverses P-gp-mediated multidrug resistance (MDR) and exhibits antitumor efficacy in mice without significant cytotoxicity .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-126940

Furanodiene	Classification of Application Fields Terpenoids Sesquiterpenes Source classification Plants Curcuma longa Disease Research Fields Cancer Zingiberaceae	Reactive Oxygen Species P-glycoprotein Apoptosis
Furanodiene is a natural terpenoid isolated from Rhizoma Curcumae. Furanodiene plays anti-cancer effects through anti-angiogenesis and inducing ROS production, DNA strand breaks and apoptosis. Furanodiene suppresseed efflux transporter *Pgp* (P-glycoprotein) function and reduced Pgp protein level .

HY-N1457

Chrysosplenetin	Flavonols Structural Classification Piscidia erythrina L. Flavonoids Classification of Application Fields Source classification Phenols Polyphenols Metabolic Disease Plants Compositae Disease Research Fields	P-glycoprotein Cytochrome P450 Ferroptosis
Chrysosplenetin is one of the polymethoxylated flavonoids in Artemisia annua L. (Compositae) and other several Chinese herbs. Chrysosplenetin inhibits *P-gp* activity and reverses the up-regulated P-gp and MDR1 levels induced by artemisinin (ART). Chrysosplenetin significantly augments the rat plasma level and anti-malarial efficacy of ART, partially due to the uncompetitive inhibition effect of Chrysosplenetin on rat CYP3A .

HY-W009141

1-Monopalmitin Glyceryl palmitate	Source classification Plants	P-glycoprotein
1-Monopalmitin, a bitter melon extract, inhibits the P-glycoprotein (P-gp) activity in intestinal Caco-2 cells .

HY-N1941

Isosinensetin	Structural Classification Flavonoids other families Classification of Application Fields Flavones Source classification Plants Inflammation/Immunology Disease Research Fields	P-glycoprotein Bacterial
Isosinensetin, a polymethoxylated flavone extracted from pericarpium citri reticulatae viride, exhibits inhibition on P-glycoprotein (P-gp) in MDR1-MDCKII cells .

HY-N2103

Tenacissoside G	Structural Classification other families Classification of Application Fields Source classification Plants Disease Research Fields Steroids Cancer	P-glycoprotein
Tenacissoside G is a C21 steroid from the stems of Marsdenia tenacissima. Tenacissoside G reverses multidrug resistance in P-glycoprotein (Pgp)-overexpressing multidrug-resistant cancer cells .

HY-N6932

Voacamine	Alkaloids Structural Classification other families Classification of Application Fields Source classification Metabolic Disease Plants Disease Research Fields Indole Alkaloids	Cannabinoid Receptor P-glycoprotein
Voacamine, an indole alkaloid, exhibits potent cannabinoid CB1 receptor antagonistic activity . Voacamine also inhibits P-glycoprotein (P-gp) action in multidrug-resistant tumor cells .

HY-N144114

P-gp inhibitor 2	Classification of Application Fields Disease Research Fields Cancer	P-glycoprotein
P-gp inhibitor 2 is a potent *P-gp* inhibitor. P-gp inhibitor 2 shows reverse Doxorubicin resistance (IC₅₀=0.22 µM) in P-gp overexpressing human colorectal carcinoma cells (SW600 Ad300) .

HY-N10562

Mutabilol	Terpenoids Labiatae Smallanthus uvedalia (Linnaeus) Mackenzie Diterpenoids Plants	P-glycoprotein
Mutabilol (compound 1) is a potent p-glycoprotein (P-gp) regulator. Mutabilol is a nature product could be isolated from Plectranthus mutabilis leaves. Mutabilol increases the P-gp expression in NCI-H460/R cells .

HY-N0689

Evodine	Alkaloids Classification of Application Fields Source classification Evodia rutaecarpa (Juss.) Benth. Rutaceae Quinoline Alkaloids Plants Disease Research Fields Cancer	P-glycoprotein
Evodine, the major limonoid of Evodiae Fuctus, is a potent *P-gp* inhibitor. Evodine has protection against glutamateinduced toxicity by preserving the antioxidant defense system .

HY-N0425

Epoxylathyrol	Structural Classification Euphorbia boetica Classification of Application Fields Terpenoids Source classification Diterpenoids Euphorbiaceae Plants Disease Research Fields Cancer	P-glycoprotein
Epoxylathyrol, an epoxylathyrane derivative isolated from the Euphorbia boetica, is a P-glycoprotein (P-gp) inhibitor. Epoxylathyrol is a P-gp-mediated multidrug resistance (MDR) reverser .

HY-N10563

Coleon-U-quinone	Structural Classification Ketones, Aldehydes, Acids Labiatae Smallanthus uvedalia (Linnaeus) Mackenzie Plants	P-glycoprotein
Coleon-U-quinone is a potent *P-gp* inhibitor. Coleon-U-quinone can inhibit cancer cells viability and sensitize multidrug resistance cancer cells to Doxorubicin (HY-15142A) .

HY-N6684

Deoxynivalenol 5+ Cited Publications Vomitoxin	Structural Classification Microorganisms Classification of Application Fields Terpenoids Sesquiterpenes Source classification Metabolic Disease Disease Research Fields	Others
Deoxynivalenol, an orally active mycotoxin of the trichothecenes family, crosses the intestinal mucosa by a paracellular pathway through the tight junctions. The Deoxynivalenol transport is not affected by P-glycoprotein (PgP) or multidrug resistance-associated proteins (MRPs) inhibitors .

HY-N10564

8α,9α-Epoxycoleon-U-quinone	Structural Classification Ketones, Aldehydes, Acids Labiatae Smallanthus uvedalia (Linnaeus) Mackenzie Plants	P-glycoprotein
8α,9α-Epoxycoleon-U-quinone (compound 3) is a p-glycoprotein (P-gp) regulator that is selective for cancer cells (SI=2.0). 8α,9α-Epoxycoleon-U-quinone effectively inhibits *P-gp* activity in NCI-H460/R cells. 8α,9α-Epoxycoleon-U-quinone also reverses the resistance of cancer cells to Doxorubicin (DOX) (HY-15142A) and enhances the anticancer effect of DOX .

HY-N4108

Hypophyllanthin	Phyllanthus urinaria Linn. Structural Classification Classification of Application Fields Source classification Lignans Euphorbiaceae Phenylpropanoids Plants Inflammation/Immunology Disease Research Fields	P-glycoprotein
Hypophyllanthin is a major lignan in Phyllanthus spp, with strong anti-inflammatory activity. Hypophyllanthin directly inhibits P-glycoprotein (P-gp) activity and did not interfere with multidrug resistance protein 2 (MRP2) activity .

HY-N7332

Pepluanin A	Structural Classification Terpenoids Source classification Euphorbia peplus Linn. Diterpenoids Euphorbiaceae Plants	P-glycoprotein
Pepluanin A is a natural compound isolated from Euphorbia peplus L. Pepluanin A shows a very high activity for a jatrophane diterpene, outperforming Cyclosporin A by a factor of at least 2 in the inhibition of Pgp-mediated Daunomycin (HY-13062A) transport ^[1]

HY-N6748

Roquefortine C 1 Publications Verification	Infection Structural Classification Microorganisms Classification of Application Fields Cyclopeptides Source classification Disease Research Fields	P-glycoprotein Cytochrome P450 Bacterial Endogenous Metabolite
Roquefortine C, a fungal cyclopeptide isolated from Penicillium roquefortii, activates *P-gp* and also inhibits P450-3A and other haemoproteins. Roquefortine C has bacteriostatic activities against Gram-positive bacteria .

HY-N7305

Jatrophane 5	Structural Classification Terpenoids Source classification Euphorbia peplus Linn. Diterpenoids Euphorbiaceae Plants	P-glycoprotein
Jatrophane 5 is a natural product of Jatropha carcas L. Jatrophane 5 has powerful inhibition of *P-gp*, higher than R(+)-verapamil (HY-14275) and Tariquidar (HY-10550) in colorectal multi-drug resistant cells (DLD1-TxR) .

HY-N4108R

Hypophyllanthin (Standard)	Phyllanthus urinaria Linn. Structural Classification Source classification Lignans Euphorbiaceae Phenylpropanoids Plants	P-glycoprotein
Hypophyllanthin (Standard) is the analytical standard of Hypophyllanthin. This product is intended for research and analytical applications. Hypophyllanthin is a major lignan in Phyllanthus spp, with strong anti-inflammatory activity. Hypophyllanthin directly inhibits P-glycoprotein (P-gp) activity and did not interfere with multidrug resistance protein 2 (MRP2) activity .

HY-N3028

Taccalonolide B	Structural Classification Classification of Application Fields Source classification Schizocapsa plantaginea Hance Plants Disease Research Fields Taccaceae Steroids Cancer	Microtubule/Tubulin
Taccalonolide B is microtubule stabilizer isolated from Tacca plantaginea, with antitumor activity. Taccalonolide B is effective in vitro against cell lines that overexpress P-glycoprotein (Pgp) and multidrug-resistance protein (MRP7). Taccalonolide B inhibits growth of SK-OV-3 cells with an IC₅₀ of 208 nM .

HY-108694

γ-Tocotrienol 1 Publications Verification	Structural Classification Monophenols Microorganisms other families Classification of Application Fields Source classification Phenols Plants Inflammation/Immunology Disease Research Fields	Endogenous Metabolite NF-κB
γ-Tocotrienol is an active form of vitamin E. γ-tocotrienol reverses the multidrug resistance (MDR) of breast cancer cells through the signaling pathway of NF-κB and P-gp. γ-Tocotrienol is also a novel radioprotector agent, can mitigate bone marrow radiation damage during targeted radionuclide treatment .

HY-17367

Atazanavir Maximum Cited Publications 11 Publications Verification BMS-232632	Infection Structural Classification Alkaloids Classification of Application Fields Source classification Pyridine Alkaloids Endogenous metabolite Disease Research Fields Cancer	HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite
Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp) . Atazanavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 3.49 μM .

HY-17367A

Atazanavir sulfate Maximum Cited Publications 11 Publications Verification BMS-232632 sulfate	Infection Structural Classification Alkaloids Classification of Application Fields Source classification Pyridine Alkaloids Endogenous metabolite Disease Research Fields Cancer	HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite
Atazanavir (BMS-232632) sulfate, a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir sulfate is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp) . Atazanavir sulfate is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 3.49 μM .

HY-N2416

Taccalonolide A	Structural Classification Classification of Application Fields Source classification Plants Disease Research Fields Tacca chantrieri Andre Taccaceae Steroids Cancer	Microtubule/Tubulin Apoptosis
Taccalonolide A is a microtubule stabilizer, which is a steroid isolated from Tacca chantrieri, with cytotoxic and antimalarial activities . Taccalonolide A causes G₂-M accumulation, Bcl-2 phosphorylation and initiation of apoptosis . Taccalonolide A is effective in vitro against cell lines that overexpress P-glycoprotein (Pgp) and multidrug resistance protein 7 (MRP7), with an IC₅₀ of 622 nM for SK-OV-3 cells .

HY-N2453

Convallatoxin	Triterpenes Structural Classification Classification of Application Fields Terpenoids Ranunculaceae Adonis amurensis Regel et Radde Plants Inflammation/Immunology Disease Research Fields	PPAR NF-κB P-glycoprotein
Convallatoxin is a cardiac glycoside isolated from Adonis amurensis Regel et Radde. Convallatoxin ameliorates colitic inflammation via activation of PPARγ and suppression of NF-κB. Convallatoxin is a P-glycoprotein (P-gp) substrate and recognized Val982 as an important amino acid involved in its transport. Convallatoxin is an enhancer of ligand-induced MOR endocytosis with high potency and efficacy. Anti-inflammatory and anti-proliferative properties .

HY-17367R

Atazanavir (Standard)	Structural Classification Alkaloids Source classification Pyridine Alkaloids Endogenous metabolite	HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite
Atazanavir (Standard) is the analytical standard of Atazanavir. This product is intended for research and analytical applications. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp) . Atazanavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 3.49 μM .

HY-108694R

γ-Tocotrienol (Standard)	Structural Classification Monophenols Microorganisms other families Source classification Phenols Plants	Endogenous Metabolite NF-κB
γ-Tocotrienol (Standard) is the analytical standard of γ-Tocotrienol. This product is intended for research and analytical applications. γ-Tocotrienol is an active form of vitamin E. γ-tocotrienol reverses the multidrug resistance (MDR) of breast cancer cells through the signaling pathway of NF-κB and P-gp. γ-Tocotrienol is also a novel radioprotector agent, can mitigate bone marrow radiation damage during targeted radionuclide treatment .

HY-17367AR

Atazanavir sulfate (Standard)	Structural Classification Alkaloids Source classification Pyridine Alkaloids Endogenous metabolite	HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite
Atazanavir (sulfate) (Standard) is the analytical standard of Atazanavir (sulfate). This product is intended for research and analytical applications. Atazanavir (BMS-232632) sulfate, a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir sulfate is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp) . Atazanavir sulfate is also a SARS-CoV 3CLpro inhibitor with an IC₅₀ of 3.49 μM .

HY-N2453R

Convallatoxin (Standard)	Triterpenes Structural Classification Terpenoids Ranunculaceae Adonis amurensis Regel et Radde Plants	PPAR NF-κB P-glycoprotein
Convallatoxin (Standard) is the analytical standard of Convallatoxin. This product is intended for research and analytical applications. Convallatoxin is a cardiac glycoside isolated from Adonis amurensis Regel et Radde. Convallatoxin ameliorates colitic inflammation via activation of PPARγ and suppression of NF-κB. Convallatoxin is a P-glycoprotein (P-gp) substrate and recognized Val982 as an important amino acid involved in its transport. Convallatoxin is an enhancer of ligand-induced MOR endocytosis with high potency and efficacy. Anti-inflammatory and anti-proliferative properties .

HY-N3584

Paris saponin VII 2 Publications Verification Chonglou Saponin VII	Structural Classification Liliaceae Classification of Application Fields Source classification Trillium tschonoskii Maxim. Plants Disease Research Fields Steroids Cancer	Akt p38 MAPK P-glycoprotein Bcl-2 Family Caspase PARP Autophagy Apoptosis
Paris saponin VII (Chonglou Saponin VII) is a steroidal saponin isolated from the roots and rhizomes of Trillium tschonoskii. Paris saponin VII-induced apoptosis in K562/ADR cells is associated with Akt/MAPK and the inhibition of *P-gp. Paris saponin VII attenuates mitochondrial membrane potential, increases the expression of apoptosis-related proteins, such as Bax and cytochrome c, and decreases the protein expression levels of Bcl-2, caspase-9, caspase-3, PARP-1, and p-Akt*. Paris saponin VII induces a robust autophagy in K562/ADR cells and provides a biochemical basis in the treatment of leukemia .

Cat. No.	Product Name	Chemical Structure

HY-135328AS

Norverapamil-d7 hydrochloride
Norverapamil-d₇ (hydrochloride) is a deuterium labeled Norverapamil. Norverapamil ((±)-Norverapamil), an N-demethylated metabolite of Verapamil, is a L-type calcium channel blocker and a P-glycoprotein (P-gp) function inhibitor[1][2].

HY-A0064S

Verapamil-d3 hydrochloride

Verapamil-d₃ (hydrochloride) is the deuterium labeled Verapamil hydrochloride. Verapamil hydrochloride ((±)-Verapamil hydrochloride) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil hydrochloride also inhibits CYP3A4. Verapamil hydrochloride has the potential for high blood pressure, heart arrhythmias and angina research[1][2][3].

HY-17367S4

Atazanavir-d6
Atazanavir-d₆ is deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration[1]. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)[2]. Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM[3].

HY-135328S

Norverapamil-d7
Norverapamil-d₇ is a deuterium labeled Norverapamil ((±)-Norverapamil). Norverapamil, an N-demethylated metabolite of Verapamil, is a L-type calcium channel blocker and a P-glycoprotein (P-gp) function inhibitor[1][2].

HY-14275S1

Verapamil-d7
Verapamil-d₇ is the deuterium labeled Verapamil (HY-14275). Verapamil ((±)-Verapamil) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil also inhibits CYP3A4. Verapamil has the potential for high blood pressure, heart arrhythmias and angina research .

HY-A0064S1

Verapamil-d6 hydrochloride

Verapamil-d₆ (CP-16533-1-d₆) hydrochloride is the deuterium labled Verapamil (hydrochloride) (HY-A0064). Verapamil hydrochloride ((±)-Verapamil hydrochloride) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil hydrochloride also inhibits CYP3A4. Verapamil hydrochloride has the potential for high blood pressure, heart arrhythmias and angina research .

HY-17367S3

Atazanavir-d5
Atazanavir-d₅ is the deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration[1]. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)[2]. Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM[3].

HY-17367S2

Atazanavir-d9
Atazanavir-d₉ is the deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration[1]. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)[2]. Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM[3].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks